Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Suzanne Grimm

Psychiatry Wisconsin Rapids, WI Medical Doctor

NPI 1245345230 CMS profile 146776

111 W Jackson St, Wisconsin Rapids, WI 54495

Open in the dashboard

General payments

$3,260

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Suzanne Grimm of Wisconsin Rapids, WI is reported in the CMS Open Payments database as having received $3,260 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $609 30
2024 General $646 31
2023 General $273 14
2022 General $33 3
2021 General $72 5
2020 General $157 6
2019 General $1,470 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suzanne Grimm
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Suzanne Grimm were reported at $609. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Suzanne Grimm Psychiatry median Middle half National median
2019 $1,470 $184 $59–$605 $163
2020 $157 $119 $36–$372 $114
2021 $72 $143 $43–$576 $132
2022 $33 $153 $50–$590 $149
2023 $273 $170 $56–$651 $160
2024 $646 $179 $57–$673 $164
2025 $609 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $472 22 payments
  2. Vanda Pharmaceuticals Inc. $412 27 payments
  3. Otsuka America Pharmaceutical, Inc. $399 21 payments
  4. Lundbeck LLC $395 41 payments
  5. AbbVie, Inc. $236 12 payments
  6. Teva Pharmaceuticals USA, Inc. $210 6 payments
  7. ITI, Inc. $123 5 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $117 10 payments
  9. Axsome Therapeutics, Inc. $117 6 payments
  10. Janssen Pharmaceuticals, Inc $114 11 payments
  11. Other $667 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,065 198 payments
  2. Education $195 4 payments
Products named General payments · program years 2019–2025
  1. FANAPT $398 26 payments
  2. HETLIOZ $358 24 payments
  3. ARISTADA Cns $321 14 payments
  4. ARISTADA Cns $321 14 payments
  5. ARISTADA Cns $321 14 payments
  6. ARISTADA Cns $321 14 payments
  7. ARISTADA INITIO $259 11 payments
  8. ABILIFY MAINTENA $246 13 payments
  9. REXULTI $201 12 payments
  10. LYBALVI $195 10 payments
  11. Other $2,376 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

6,811

Median for Psychiatry: 574

Drug cost

$2,010,611

Median for Psychiatry: $27,624

Branded share of claims

24.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 53 $429,111
Invega Trinza Paliperidone Palmitate Brand 38 $343,939
Abilify Maintena Aripiprazole Brand 99 $277,859
Aristada Aripiprazole Lauroxil Brand 64 $183,080
Invega Sustenna Paliperidone Palmitate Brand 57 $169,150
Abilify Asimtufii Aripiprazole Brand 14 $81,153
Risperdal Consta Risperidone Microspheres Brand 29 $71,469
Vraylar Cariprazine Hcl Brand 49 $70,940
Perseris Risperidone Brand 17 $44,816
Clozapine Generic 369 $43,659

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$15,933

Medicare's payments for the services billed

Medicare patients

101

Average age 56

Services billed

227

53 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 40%
Depression 38%
Diabetes 26%
Chronic kidney disease 16%
Arthritis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ABILIFY MAINTENA
  • Lundbeck LLC $76
  • Otsuka America Pharmaceutical, Inc. $20
$97 99 —
LYBALVI
  • Alkermes, Inc. $83
$83 12 —
VRAYLAR
  • AbbVie, Inc. $68
$68 49 —
REXULTI
  • Lundbeck LLC $55
$55 19 —
Auvelity
  • Axsome Therapeutics, Inc. $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record